Payment overview · 2025
General Payments
$33,874.72
215 reported records · 32 companies
Healthcare provider profile · identity verified
Farrukh A Kureishy, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CLINTON, IL · NPI 1619950060
Verified facts
What the public records show
CMS Open Payments records show Farrukh A Kureishy, MD received $33,874.72 in general payments during 2025 across 215 reported records.
Neurocrine BioSciences, Inc. accounted for 70.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Eliquis, Entresto, Farxiga, Gemtesa, Ingrezza, Ozempic, Paxlovid, Rexulti, Trelegy Ellipta, Trintellix, Wegovy, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1237 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Trelegy Ellipta by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Caplyta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 333 claims for Ingrezza by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Wegovy by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1237 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Aptiom by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $23,988.29 | 70.8% | 35 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $6,802.92 | 20.1% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $604.44 | 1.8% | 18 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $289.96 | 0.9% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $286.02 | 0.8% | 21 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $275.28 | 0.8% | 27 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $247.98 | 0.7% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $151.46 | 0.5% | 15 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $143.37 | 0.4% | 15 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $112.03 | 0.3% | 5 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $88.14 | 0.3% | 4 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $82.62 | 0.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $82.58 | 0.2% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $81.60 | 0.2% | 5 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $64.35 | 0.2% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $61.84 | 0.2% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $58.77 | 0.2% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $52.02 | 0.1% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $51.49 | 0.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.46 | 0.1% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $47.24 | 0.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $46.89 | 0.1% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $45.52 | 0.1% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.62 | 0.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.30 | 0.1% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $19.34 | 0.1% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $18.40 | 0.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.97 | 0.1% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$16.12 | 0.1% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.16 | 0.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $13.92 | 0.0% | 1 | 2025 |
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $5.62 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $21,021.00 | 7 |
| Consulting Fee | $5,800.00 | 1 |
| Food and Beverage | $4,239.91 | 192 |
| Travel and Lodging | $2,765.27 | 13 |
| Education | $48.54 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $23,988.29 | 35 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $6,802.92 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $375.60 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $371.10 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $353.67 | 5 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $289.96 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $275.28 | 27 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $247.98 | 12 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $211.96 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $198.91 | 15 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $151.46 | 15 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $151.46 | 15 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $143.37 | 15 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $112.03 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $108.73 | 6 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $88.14 | 4 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $82.62 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $82.58 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $81.60 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $78.42 | 12 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $64.35 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $58.77 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.53 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $51.49 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $51.46 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $47.24 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $45.52 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $45.31 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $34.10 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $30.62 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.43 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $28.57 | 6 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $22.30 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $5.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1237 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 99 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 125 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 122 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 333 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 118 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 26 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 102 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 100 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
125 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1237 | 123 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
100 | 21 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
223 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
102 | 13 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
333 | 21 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
99 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
118 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
102 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
76 | 76 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1237 | 123 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 25 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
84 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
122 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1262 | 222 |
| Eliquis | Apixaban | 1237 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1199 | 194 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1172 | 192 |
| Losartan Potassium | Losartan Potassium | 1068 | 221 |
| Gabapentin | Gabapentin | 879 | 139 |
| Potassium Chloride | Potassium Chloride | 821 | 118 |
| Metoprolol Succinate | Metoprolol Succinate | 789 | 155 |
| Duloxetine Hcl | Duloxetine Hcl | 739 | 126 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 700 | 175 |
| Furosemide | Furosemide | 595 | 102 |
| Lisinopril | Lisinopril | 552 | 90 |
| Omeprazole | Omeprazole | 529 | 128 |
| Tramadol Hcl | Tramadol Hcl | 508 | 104 |
| Famotidine | Famotidine | 457 | 95 |
| Metoprolol Tartrate | Metoprolol Tartrate | 457 | 81 |
| Quetiapine Fumarate | Quetiapine Fumarate | 437 | 60 |
| Mirtazapine | Mirtazapine | 431 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 422 | 77 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 409 | 76 |
| Metformin Hcl | Metformin Hcl | 390 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 386 | 67 |
| Trazodone Hcl | Trazodone Hcl | 375 | 52 |
| Sertraline Hcl | Sertraline Hcl | 372 | 58 |
| Carvedilol | Carvedilol | 371 | 73 |
| Metformin Hcl Er | Metformin Hcl | 365 | 83 |
| Torsemide | Torsemide | 353 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 352 | 81 |
| Donepezil Hcl | Donepezil Hcl | 346 | 56 |
| Levetiracetam | Levetiracetam | 343 | 42 |
| Ingrezza | Valbenazine Tosylate | 333 | 21 |
| Prednisone | Prednisone | 297 | 120 |
| Spironolactone | Spironolactone | 286 | 60 |
| Warfarin Sodium | Warfarin Sodium | 283 | 13 |
| Lorazepam | Lorazepam | 282 | 51 |
| Memantine Hcl | Memantine Hcl | 263 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 261 | 58 |
| Xarelto | Rivaroxaban | 259 | 31 |
| Buspirone Hcl | Buspirone Hcl | 252 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 247 | 89 |
| Escitalopram Oxalate | Escitalopram Oxalate | 231 | 42 |
| Jardiance | Empagliflozin | 223 | 29 |
| Allopurinol | Allopurinol | 221 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 203 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 193 | 42 |
| Alprazolam | Alprazolam | 185 | 36 |
| Doxazosin Mesylate | Doxazosin Mesylate | 178 | 32 |
| Simvastatin | Simvastatin | 178 | 39 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 173 | 32 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 170 | 30 |
| Divalproex Sodium | Divalproex Sodium | 165 | 23 |
| Cephalexin | Cephalexin | 162 | 92 |
| Clonidine Hcl | Clonidine Hcl | 157 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 154 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 153 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 44 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 137 | 20 |
| Ezetimibe | Ezetimibe | 133 | 31 |
| Meloxicam | Meloxicam | 133 | 31 |
| Montelukast Sodium | Montelukast Sodium | 133 | 32 |
| Myrbetriq | Mirabegron | 127 | 16 |
| Baclofen | Baclofen | 126 | 18 |
| Farxiga | Dapagliflozin Propanediol | 125 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 122 | 21 |
| Gemtesa | Vibegron | 122 | suppressed |
| Topiramate | Topiramate | 122 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 121 | 33 |
| Ozempic | Semaglutide | 118 | 16 |
| Pregabalin | Pregabalin | 116 | 19 |
| Doxepin Hcl | Doxepin Hcl | 114 | 17 |
| Latanoprost | Latanoprost | 114 | 27 |
| Incruse Ellipta | Umeclidinium Bromide | 111 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 109 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 108 | 23 |
| Lamotrigine | Lamotrigine | 107 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 105 | 27 |
| Rexulti | Brexpiprazole | 102 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 100 | 21 |
| Entresto | Sacubitril/Valsartan | 99 | 12 |
| Primidone | Primidone | 98 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 95 | 14 |
| Azelastine Hcl | Azelastine Hcl | 93 | 17 |
| Nystatin | Nystatin | 91 | 57 |
| Ondansetron Hcl | Ondansetron Hcl | 91 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 19 |
| Clonazepam | Clonazepam | 87 | 17 |
| Finasteride | Finasteride | 86 | 19 |
| Aptiom | Eslicarbazepine Acetate | 84 | suppressed |
| Bupropion Xl | Bupropion Hcl | 84 | 19 |
| Cefuroxime | Cefuroxime Axetil | 81 | 53 |
| Breo Ellipta | Fluticasone/Vilanterol | 80 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 79 | 16 |
| Olanzapine | Olanzapine | 79 | 17 |
| Nifedipine Er | Nifedipine | 78 | 16 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 76 | 76 |
| Paroxetine Hcl | Paroxetine Hcl | 76 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 75 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 75 | 27 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 74 | 33 |
| Oxcarbazepine | Oxcarbazepine | 74 | suppressed |
| Sucralfate | Sucralfate | 74 | 11 |
| Levofloxacin | Levofloxacin | 73 | 41 |
| Glipizide | Glipizide | 72 | 15 |
| Tradjenta | Linagliptin | 71 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 69 | 37 |
| Amiodarone Hcl | Amiodarone Hcl | 68 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 68 | 12 |
| Risperidone | Risperidone | 68 | 18 |
| Novolog Flexpen | Insulin Aspart | 66 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 65 | 20 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 64 | 37 |
| Ondansetron Odt | Ondansetron | 63 | 27 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 63 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 60 | 22 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 56 | suppressed |
| Glimepiride | Glimepiride | 56 | 13 |
| Amantadine | Amantadine Hcl | 55 | suppressed |
| Carbamazepine | Carbamazepine | 55 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 55 | suppressed |
| Brilinta | Ticagrelor | 54 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 54 | 13 |
| Enoxaparin Sodium | Enoxaparin Sodium | 53 | suppressed |
| Lactulose | Lactulose | 53 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 50 | suppressed |
| Calcitriol | Calcitriol | 50 | 13 |
| Amoxicillin | Amoxicillin | 49 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 12 |
| Bumetanide | Bumetanide | 47 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 47 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 46 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 46 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 45 | suppressed |
| Digoxin | Digoxin | 45 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 45 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 45 | suppressed |
| Aripiprazole | Aripiprazole | 44 | 14 |
| Azithromycin | Azithromycin | 44 | 34 |
| Dapagliflozin | Dapagliflozin Propanediol | 44 | 12 |
| Fentanyl | Fentanyl | 43 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 43 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 43 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 42 | 14 |
| Sevelamer Carbonate | Sevelamer Carbonate | 42 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | 11 |
| Ranolazine Er | Ranolazine | 40 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 39 | suppressed |
| Methimazole | Methimazole | 39 | suppressed |
| Atenolol | Atenolol | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 28 |
| Enalapril Maleate | Enalapril Maleate | 38 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 28 |
| Naproxen | Naproxen | 37 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 36 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 36 | suppressed |
| Sulfasalazine | Sulfasalazine | 36 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Drizalma Sprinkle | Duloxetine Hcl | 33 | suppressed |
| Fluconazole | Fluconazole | 33 | 21 |
| Methotrexate | Methotrexate Sodium | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | suppressed |
| Ketoconazole | Ketoconazole | 31 | 14 |
| Nyamyc | Nystatin | 31 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Novolog | Insulin Aspart | 30 | suppressed |
| Ursodiol | Ursodiol | 30 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 29 | 15 |
| Celecoxib | Celecoxib | 29 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 11 |
| Nitroglycerin | Nitroglycerin | 29 | 25 |
| Prednisolone Acetate | Prednisolone Acetate | 29 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 28 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Rivastigmine | Rivastigmine | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 27 | suppressed |
| Clonidine | Clonidine | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | suppressed |
| Timolol Maleate | Timolol Maleate | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 25 |
| Phenytoin | Phenytoin | 26 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | 11 |
| Lithium Carbonate | Lithium Carbonate | 25 | suppressed |
| Metronidazole | Metronidazole | 25 | 12 |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Acetazolamide | Acetazolamide | 24 | suppressed |
| Caplyta | Lumateperone Tosylate | 24 | suppressed |
| Klor-Con M10 | Potassium Chloride | 24 | suppressed |
| Nystop | Nystatin | 24 | 12 |
| Tiotropium Bromide | Tiotropium Bromide | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Dofetilide | Dofetilide | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Novolin R | Insulin Regular, Human | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Ertapenem | Ertapenem Sodium | 20 | 11 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 20 | suppressed |
| Restasis | Cyclosporine | 20 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 19 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 19 | suppressed |
| Insulin Aspart | Insulin Aspart | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Mirabegron Er | Mirabegron | 19 | suppressed |
| Scopolamine | Scopolamine | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 18 | 15 |
| Metolazone | Metolazone | 18 | suppressed |
| Praluent Pen | Alirocumab | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | 13 |
| Insulin Lispro | Insulin Lispro | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 17 | suppressed |
| Meropenem-0.9% Nacl | Meropenem-0.9% Sodium Chloride | 16 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 16 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 16 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 15 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 15 | 13 |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Wegovy | Semaglutide | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 14 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Glucagon Emergency Kit | Glucagon | 14 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 14 | suppressed |
| Ofloxacin | Ofloxacin | 14 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Meropenem | Meropenem | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Galantamine Er | Galantamine Hbr | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Ongentys | Opicapone | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Dupixent Syringe | Dupilumab | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $33,874.72 · 215 records | Neurocrine BioSciences, Inc. | AIRSUPRA, AREXVY, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, INGREZZA, INSPIRE, KISUNLA, Kerendia, LEQVIO, NEXLETOL, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PAXLOVID, QULIPTA, REPATHA, REXULTI, REZDIFFRA, Rybelsus, SPINRAZA, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, WATCHMAN Access System, Wegovy, ZAVZPRET, ZENPEP, Zunveyl | 24 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error